Our universities need to commit to global needs-driven research and development (R&D) for new medicines, vaccines, and diagnostics. Further, our universities should enact active policies that guarantee affordable access to the end-products of university research.

To do this, universities should:

- Make sure drugs that come from their research are affordable, and not overpriced.
Adopt Equitable Access Licensing policies for all medicines, vaccines and  diagnostics produced from university research.

- Separate research from commercial interests.
Engage with innovative R&D frameworks, embracing the principle of separating (“de-linking”) the cost of R&D from the price of the resulting treatment.

Achieve a goal of receiving 20% of all research funding from non-traditional push & pull mechanisms by 2020, using internal incentives, participation in larger delinkage schemes and strategic non-profit partnerships.

- Call for government to address imbalances in research funding, and support important but underfunded areas of research.
Demand needs-driven funding mechanisms from government and philanthropic sources to reflect the global burden of diseases, including increasing spending on neglected diseases to 0.01% of GDP.